Allogeneic CD34+ hematopoietic stem cell graft (CD34+ HSC graft)

An allogeneic CD34+ hematopoietic stem cell graft is a therapeutic cell product consisting of hematopoietic stem and progenitor cells (HSPCs) harvested from a healthy donor and administered to a recipient to restore blood and immune function. These grafts are characterized by the presence of the CD34 surface marker, a transmembrane phosphoglycoprotein used to identify and often enrich the stem cell population required for successful engraftment (StatPearls, 2023). The primary biological role of the graft is to reconstitute the recipient's hematopoietic system following myeloablative or reduced-intensity conditioning, providing a source for all blood cell lineages including erythrocytes, leukocytes, and platelets (NCI, 2024). In the context of hematologic malignancies, the graft also facilitates a graft-versus-leukemia (GVL) effect, where donor-derived immune cells recognize and eliminate residual malignant cells. Clinical management of these grafts involves complex interactions with conditioning agents like busulfan and immunosuppressive drugs like tacrolimus to prevent graft-versus-host disease (GVHD) while ensuring robust donor chimerism (PubMed, PMID: 24561243).

Other names

Allo-HSCTCD34-selected hematopoietic stem cell graftAllogeneic hematopoietic stem cell transplantPurified CD34+ stem cell graftCD34+ selected peripheral blood stem cells

The graft functions by homing to the recipient's bone marrow niche, where the CD34+ hematopoietic stem cells engraft and differentiate into all blood cell lineages. This process restores normal hematopoiesis and provides a donor-derived immune system that can recognize and eliminate residual malignant cells through the graft-versus-leukemia (GVL) effect.